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Summary 
 
 Altrenogest, marketed for use in horses as 
Regumate, is a synthetic progestin that is mar-
keted for use in pigs as MATRIX.  It effec-
tively regulates the occurrence of estrus in 
randomly cycling gilts if it is provided for 14 
or more days at a daily dose of 15 mg/day.  It 
is important to assure that each gilt receives 
her full dose; otherwise problems of cystic 
follicles and reduced fertility may be ob-
served.  
 
(Key Words:  Pigs, Estrous Synchronization, 
Altrenogest.) 
 
Introduction 
 
 It has long been recognized that gilts con-
stitute a challenge for swine breeding herds. 
Gilts are expensive, they occupy valuable 
space, and the occurrence of estrus in gilts 
may not fit the production schedule.  Produc-
tion managers often view gilts with skepti-
cism, and most would opt for eliminating the 
first pregnancy cycle and going right to the 
second parity if there was a method to do it.   
 
 Gilts are unavoidable, however, and make 
up 20 to 50% of breeding herds.  The gilt pool 
provides a management system to minimize 
problems with gilt breedings, but the unpre-
dictable occurrence of estrus in gilts creates 
additional labor and housing costs.  Many 
production units opt for one or both of the fol-
lowing strategies: 1) house excess gilts to 
make up for shortages on some weeks, 2) 
check estrus but not breed at first detected es-
trus, thus allowing service to occur at a second 
or later postpubertal estrus, and providing  
 
some ability to predict future occurrence of 
estrus and plan for excesses and shortfalls in 
the availability of gilts in a particular week. 
 
 Researchers began attempting to regulate 
the estrous cycle of pigs at least 50 years ago.  
The development of prostaglandin F2α prod-
ucts provided a method to regulate the estrous 
cycle of several species of farm animals, but 
not pigs.  The mechanism of prostaglandin 
products is to regress the corpora lutea (CL), 
thus causing an early entry into proestrus, but 
the pig CL are resistant to the effects of pros-
taglandin F2α until very late in their cycle and 
a practical method to use them has not been 
forthcoming.  Some have inseminated gilts, 
then used prostaglandin F2α  to induce abor-
tion followed by a fertile heat, but this is too 
cumbersome for routine use.   
 
 Soon after synthetic progestins became 
available, there were many attempts to admin-
ister these to pigs as a part of the daily feed for 
the purpose of estrous synchronization.  To be 
useful, the progestins should group the es-
truses of gilts at a reliable interval after the 
end of progestin treatment, and provide fertil-
ity equal to untreated controls.  Experiments 
with these initial products revealed two things: 
 
 1) with the progestins tested, a relatively 
low dose would suppress estrus, but often re-
sulted in follicular cysts, rather than the 
growth of normal follicles and ovulation. 
 
 2) doses high enough to suppress the for-
mation of follicular cysts led to poor synchro-
nization of estrus and even lack of estrus. 
Faulty sperm transport was also a problem.  
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 Among the initial progestins tested was 
melengesterol acetate (MGA), a product used 
to suppress estrus in feedlot heifers and as a 
part of some synchronization protocols in cat-
tle.  Results of the earlier trials clearly indicate 
that MGA will not be useful for synchronizing 
estrus in pigs.  
 
 In the middle 1970s, the first experiments 
were conducted at Abbott Laboratories with a 
progestin that proved unique in its ability to 
synchronize estruses in gilts.  The progestin 
has been identified by several names, includ-
ing allyl trenbolone and altrenogest, and has 
been marketed for use in horses as Regumate 
for some time.  Recently, Intervet, Inc. has 
secured approval to market the formulation 
long used in horses for use in pigs.  The prod-
uct, MATRIX, is supplied as a solution con-
taining 0.22% (2.2 mg/mL) altrenogest.  The 
label indicates a treatment administering 6.8 
mL (15 mg altrenogest) per gilt once daily for 
14 consecutive days.  
 
 Gilts should be treated on an individual-
animal basis by top-dressing MATRIX on a 
portion of each gilt's daily feed allowance.  
The rest of this paper will describe the re-
search leading to this recommendation and 
will explain the mechanism of action of al-
trenogest for regulating estrous cycles in gilts.   
  
Effectiveness of Altrenogest 
 
 When post-pubertal (cycling) gilts are 
treated with altrenogest for 14 or 18 days, fol-
lowed by cessation of altrenogest treatment, 
there is a grouping of estruses between 4 and 
10 days after the last altrenogest treatment.  
The peak in occurrence of first estrus is gener-
ally from 5 to 7 days after last treatment.  The 
data in Figure 1 illustrate the estrous response 
in cycling control gilts and those treated with 
altrenogest.  This response has proven to be 
repeatable, and the estruses of 85% or more of 
cycling gilts can be scheduled to a 5-day in-
terval, with the majority of estruses occurring 
in a 2- to 3-day interval. 
 
 
Figure 1.  Occurrence of Estrus in Cycling 
Gilts Not Treated (control) or Treated with 
Altrenogest (15 mg/day) for 18 Days.  Day 0 
is the last day of altrenogest treatment.  
 
 
Required Dose to Regulate Estrous 
 
 A well designed, two-stage study was 
conducted at five locations in the United 
States to identify the daily dose of altrenogest 
required to synchronize estrus.  Gilts that were 
known to be having regular estrous cycles 
were treated with increasing doses of altreno-
gest daily for 18 consecutive days.  The data 
indicated that daily doses less than 12.5 
mg/day result in increased incidence of cystic 
follicles.  Many gilts with cysts at the lower 
daily doses had multiple cysts and experi-
enced failures to conceive.   
 
 These studies resulted in the recommenda-
tion that 15 mg/day be provided to each gilt to 
provide a small margin of safety.  Reliably 
administering this dose requires treatment of 
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individual gilts.  Attempts to feed altrenogest 
to groups of gilts have met with poor syn-
chrony of estrus, reduced numbers of gilts ex-
hibiting estrus, and with reduced fertility.    
 
Recommended Duration of Treatment 
 
 The initial studies evaluated gilts provided 
altrenogest for 18 days.  In theory, however, 
14 days should be adequate because the CL of 
gilts regress on days 14 to 16 of their estrous 
cycles.  Comparison of 14- and 18-day dura-
tions of treatment is presented in Figure 2.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Effect on the Onset of Estrus of 
Treating Gilts with Altrenogest (15 mg/day) 
for 14 or 18 Days.  The last day of altrenogest 
treatment is day 0.  (Drawn from data in Ste-
venson and Davis, J. Anim. Sci. 55:119-123, 
1982).  
 
 
 The onset of estrus may be somewhat 
more synchronous with the 18-day treatment 
but for practical applications 14 days is ade-
quate.  
 
Fertility After Altrenogest Treatment 
 
 Numerous trials have evaluated the con-
ception rate, farrowing rate, and litter size af-
ter treating gilts with altrenogest.  The results 
indicate no effects of altrenogest on these 
traits.  In some experiments there is a slight 
improvement in litter size for altrenogest-
treated gilts.  This may result from the more 
predictable time of estrus onset, and thus more 
ideal timing of insemination.  In some ex-
periments ovulation rate is increased by al-
trenogest treatment but this has not been con-
sistently observed.  
 
Conclusions 
 
 Altrenogest, the active ingredient in MA-
TRIX, has been adequately evaluated in con-
trolled experiments and field observation and, 
if administered in a way that provides 15 mg 
daily for 14 days, it is effective for regulating 
the estruses of cycling gilts such that 85% or 
more will express estrus 4 to 10 days after last 
treatment with altrenogest. 
 
 
 
 
 
 
 
